IMAGING OXYGEN METABOLISM IN BRAIN
大脑中氧代谢成像
基本信息
- 批准号:6056640
- 负责人:
- 金额:$ 3.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-09-01 至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (Adapted from applicant's abstract): Ischemic stroke is a
common and devastating disorder. The long-term goal of this project is to
develop a tool to study the pathophysiology of stroke and in particular the
ischemic penumbra. In the ischemic core blood flow is <20 percent of normal
and metabolism is almost absent. The peripheral regions also have reduced
blood flow (20 to 50 percent of normal) but are only slightly hypometabolic.
This region is called the "ischemic penumbra". It has been shown that this
region can be salvaged with early treatment. These areas are also involved
in active protein synthesis which is thought to endow ischemic tolerance.
The applicant hypothesizes that in vivo magnetic resonance imaging (MRI) of
oxygen consumption can distinguish penumbral regions from infarcted regions
in the setting of focal ischemia. In order to test this hypothesis the
applicant proposes to develop novel MR methods to image cerebral oxygen
metabolism and blood flow. The methods are based on indirect detection of
the 17-0 nucleus using 1H MRI, which has already been demonstrated to be a
sensitive technique. The applicant will evaluate this method in normal rats
and validate it against existing methods for measuring cerebral oxygen
metabolism. He will then use this method to study a reversible model of
stroke involving occlusion of middle cerebral artery. The phenomenon of
ischemic tolerance will be investigated by correlating MR data with
immunohistochemical assays for protein expression. In this way, he hopes to
be able to correlate MR images with protein synthesis. This project will
greatly enhance our understanding of the pathophysiology of stroke and
possibly provide a tool with which to noninvasively assess genetic
therapies.
描述(摘自申请者的摘要):缺血性中风是一种
常见且破坏性的疾病。这个项目的长期目标是
开发一种工具来研究中风的病理生理学,特别是
缺血半暗带。在缺血的核心血流量是正常的20%
新陈代谢几乎是不存在的。周边区域也减少了
血流量(正常的20%至50%),但仅有轻微的代谢不足。
这个区域被称为“缺血半暗带”。事实证明,这一点
早期治疗可以挽救该区域。这些领域也涉及到
在被认为具有缺血耐受性的活性蛋白质合成中。
申请人假设在活体磁共振成像(MRI)
氧耗量可以区分半影区和梗死区
在局灶性脑缺血的背景下。为了检验这一假设,
申请人提议开发新的磁共振方法来成像脑氧
新陈代谢和血液流动。这些方法是基于对
17-0核的核磁共振,这已经被证明是一个
敏感的技术。申请者将在正常大鼠身上评估这种方法
并与现有的测量脑氧含量的方法进行对比验证
新陈代谢。然后,他将使用这种方法来研究一个可逆的模型
卒中涉及大脑中动脉闭塞。这一现象
缺血耐受性将通过将磁共振数据与
免疫组织化学方法检测蛋白表达。通过这种方式,他希望
能够将磁共振图像与蛋白质合成联系起来。这个项目将
大大提高我们对中风和中风的病理生理学的认识
可能提供一种工具,用来非侵入性地评估基因
治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
UMAMAHESWAR DUVVURI其他文献
UMAMAHESWAR DUVVURI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('UMAMAHESWAR DUVVURI', 18)}}的其他基金
Novel Targets to Treat Head & Neck Cancer in Veterans
治疗头部的新目标
- 批准号:
10512034 - 财政年份:2021
- 资助金额:
$ 3.69万 - 项目类别:
Inhibition of lysosomal flux in carcinogen-induced head and neck cancer
抑制致癌物诱发的头颈癌中的溶酶体通量
- 批准号:
10306375 - 财政年份:2019
- 资助金额:
$ 3.69万 - 项目类别:
Inhibition of lysosomal flux in carcinogen-induced head and neck cancer
抑制致癌物诱发的头颈癌中的溶酶体通量
- 批准号:
10542340 - 财政年份:2019
- 资助金额:
$ 3.69万 - 项目类别:
Inhibition of lysosomal flux in carcinogen-induced head and neck cancer
抑制致癌物诱发的头颈癌中的溶酶体通量
- 批准号:
10993897 - 财政年份:2019
- 资助金额:
$ 3.69万 - 项目类别:
Novel targets to treat head and neck cancer in Veterans
治疗退伍军人头颈癌的新靶点
- 批准号:
9138391 - 财政年份:2016
- 资助金额:
$ 3.69万 - 项目类别:
QUANTIFICATION OF GENE EXPRESSION W/ LABELED ANTIBODIES: GENE THER, HIV VACCINE
使用标记抗体对基因表达进行定量:基因、HIV 疫苗
- 批准号:
6252184 - 财政年份:1997
- 资助金额:
$ 3.69万 - 项目类别:














{{item.name}}会员




